29 June 2022
: Case report 
Acute Hepatitis with Positive Autoantibodies: A Case of Natalizumab-Induced Early-Onset Liver Injury
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction, Educational Purpose (only if useful for a systematic review or synthesis)
Marlone Cunha-Silva
1ABCDEF*, Priscilla Brito Sena de Moraes 1ABCDEF, Pedro Rodrigues de Carvalho 2ABEF, Larissa Bastos Eloy da Costa 3BDEF, Guilherme Rossi Assis-Mendonça 3BCE, Cristina Alba Lalli 2BCE, Gisele Conte Alves Fernandes 1BCDE, Fernanda Bocchi Monteiro 1BDE, Gustavo Manginelli Lamas 4BEF, Alfredo Damasceno 4BDE, Daniel Ferraz de Campos Mazo 1CDF, Tiago Sevá-Pereira 1DF
DOI: 10.12659/AJCR.936318
Am J Case Rep 2022; 23:e936318
Figure 2. (A) Low magnification of liver parenchyma, exhibiting initial architectural distortion with pericellular fibrosis and delicate septa (arrows), due to recent extracellular matrix deposition (Masson trichrome stain, 4×). (B) Medium magnification of portal area with an acute and chronic infiltrate, ductular reaction (arrow head), and prominent cholestasis (*). Ballooning degeneration and apoptotic hepatocytes (arrow) and spotty inflammation are seen in the adjacent lobule (H&E stain, 10×). (C) Mild epithelial damage of the bile duct (arrow) without ductopenia (H&E stain, 10×).